Endocrine Oncology Unit, Brazilian National Cancer Institute - INCA, Rio de Janeiro/RJ, Brazil.
Nuclear Medicine Service, Brazilian National Cancer Institute - INCA, Rio de Janeiro/RJ, Brazil.
Endocrine. 2021 Aug;73(2):398-406. doi: 10.1007/s12020-021-02647-8. Epub 2021 Feb 11.
Around 10-27% of patients will present elevated thyroglobulin (Tg) levels and negative diagnostic whole-body scan (dxWBS) during differentiated thyroid cancer (DTC) follow-up. Empiric radioactive iodine (RAI) therapy in this context is controversial due to the lack of good quality studies in the context. The main purpose of this study is to compare long-term response to therapy status and overall survival between empiric RAI treated and untreated DTC patients.
A retrospective study comparing differentiated thyroid cancer patients with negative diagnostic whole-body scan and elevated thyroglobulin levels submitted or not to empiric radioactive iodine therapy in a thyroid cancer referral center. The main outcome measures were ATA Response to Therapy Stratification at 6-12 months after RAI ablative dose, at 6-18 months after negative dxWBS and last follow-up visits.
Overall, 120 DTC patients with stimulated Tg >10 ng/ml and negative dxWBS were included in this study. Overall, 53 patients were submitted to empiric RAI and 67 were in the control group. No difference was observed in ATA Response to Therapy Stratification after RAI ablation or at the end of follow-up between groups. Also, no difference was found in terms of Tg changes response. After more than 10 years of follow-up, 17 patients died (13 from treated and 4 from untreated group).
Empiric RAI treatment was not associated with better long-term ATA response to therapy status or overall survival.
在分化型甲状腺癌(DTC)随访期间,约有 10-27%的患者会出现甲状腺球蛋白(Tg)水平升高和诊断性全身扫描(dxWBS)阴性。由于缺乏高质量的研究,在这种情况下经验性放射性碘(RAI)治疗存在争议。本研究的主要目的是比较经验性 RAI 治疗和未治疗的 DTC 患者的长期治疗反应和总体生存情况。
这是一项回顾性研究,比较了甲状腺癌转诊中心中诊断性全身扫描阴性且甲状腺球蛋白水平升高的 DTC 患者是否接受经验性放射性碘治疗。主要观察指标为 RAI 消融剂量后 6-12 个月、dxWBS 阴性后 6-18 个月和最后随访时的 ATA 治疗反应分层。
本研究共纳入 120 例刺激性 Tg>10ng/ml 且 dxWBS 阴性的 DTC 患者。其中 53 例患者接受了经验性 RAI 治疗,67 例患者为对照组。两组患者在 RAI 消融后或随访结束时的 ATA 治疗反应分层无差异。此外,两组患者 Tg 变化反应也无差异。随访超过 10 年后,17 例患者死亡(治疗组 13 例,未治疗组 4 例)。
经验性 RAI 治疗与长期 ATA 治疗反应状态或总体生存无相关性。